Stockscreener 앱 받기
58.36
2.56%
1.407
전일 마감가:
$56.95
열려 있는:
$57.05
하루 거래량:
4.85M
Relative Volume:
0.43
시가총액:
$119.17B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
16.38
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
+1.51%
1개월 성능:
+3.86%
6개월 성능:
+3.16%
1년 성능:
+25.80%
1일 변동 폭
$57.04
$59.19
1주일 범위
$56.78
$59.44
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.35 | 121.18B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,152.47 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.22 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
246.53 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.32 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.45 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb Co (BMY) Shares Fall 4.0% -- What GF Score of 76 Tells Investors - GuruFocus
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement - TradingKey
Bristol Myers Squibb (BMY) Following FDA Acceptance Has An Undervalued Case - simplywall.st
Bristol-Myers Sues Aurobindo to Block Camzyos Heart Drug Copies - Bloomberg Law News
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio? - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Motley Fool
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled - TradingKey
Bristol Myers Squibb (BMY) FDA Accepts New Drug Application for Mezigdomide - GuruFocus
Bristol Myers Squibb stock holds steady on pipeline focus and oncology portfolio updates - Ad Hoc News
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Benzinga
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays central to the lon - Ad Hoc News
BMY: FDA Accepts New Drug Application for Mezigdomide in Multiple Myeloma Treatment - GuruFocus
FDA accepts Bristol Myers Squibb’s mezigdomide application - Investing.com
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma - Yahoo Finance
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline underpins long-term outl - ad-hoc-news.de
Did FTSE Russell’s Reclassification and Dividend Streak Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Is Bristol-Myers Squibb (BMY) Cheap As Index Changes Reshape Investor Exposure? - Yahoo Finance
BMY Stock Quote Price and Forecast - CNN
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - TradingView
Bristol Myers Squibb Stock And 2 Dividend Defensives For Volatile Markets - simplywall.st
Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky - Yahoo Finance
Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect - Yahoo Finance
Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY? - Yahoo Finance
Bristol Myers Squibb (BMY) Stock Still Looks Undervalued Despite Mixed Risks - simplywall.st
Bristol Myers Squibb (BMY) Stock Looks Cheap On Earnings But Mixed On Value - Yahoo Finance
Bristol-Myers Squibb balances patent headwinds and pipeline bets - AD HOC NEWS
Opdivo from Bristol-Myers Squibban immunotherapy workhorse in lung cancer care - AD HOC NEWS
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ - Fierce Biotech
Bristol Myers Squibb outlines long-term strategy for innovative medicines - AD HOC NEWS
Eaton Vance Focused Value Opportunities Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Classic Value Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb (BMY) Stock Analysis: A Steady Dividend Yield With A Strategic Edge - DirectorsTalk Interviews
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know. - Yahoo Finance
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BMYBristol-Myers Squibb Co Volatility & Greeks - Finviz
Bristol Myers Squibb: Pain First, Payoff Later? - Seeking Alpha
Merck & Bristol Myers Squibb are key partners in trials. Ex... - Moomoo
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Insider Monkey
Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued? - simplywall.st
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Hires Lobbyist on Drug Pricing - Legis1
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Investigations Launched into Bristol Myers Squibb (BMY) and Othe - GuruFocus
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
Beeline ups its Series A round for immune drug work - BioPharma Dive
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.96%
자본화:
|
볼륨(24시간):